




- (51) **International Patent Classification:**  
C07D 471/04 (2006.01) A61K 31/437 (2006.01)
- (21) **International Application Number:**  
PCT/IB2013/059768
- (22) **International Filing Date:**  
30 October 2013 (30.10.2013)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/723,995 8 November 2012 (08.11.2012) US
- (71) **Applicant:** PFIZER INC. [US/US]; 235 East 42nd Street, New York, New York 10017 (US).
- (72) **Inventors:** DAVOREN, Jennifer E.; 2456 Massachusetts Ave #105, Cambridge, Massachusetts 02140 (US). DOUNAY, Amy Beth; 21 E. Caramillo Street, Colorado Springs, Colorado 80907 (US). EFREMOV, Ivan V.; 83 Payson Road, Brookline, Massachusetts 02467 (US). GRAY, David L. F.; 26 Orion Way, Groton, Massachusetts 01450 (US). MENTE, Scot R.; 48 Arlmont Street, Arlington, Massachusetts 02476 (US). O'NEIL, Steven V.; 2 Pear Grove, East Lyme, Connecticut 06333 (US). ROGERS, Bruce N.; 19 Lawndale Street, Belmont, Massachusetts 02478 (US). SUBRAMANYAM, Chakrapani; 314 Great Pond Road, South Glastonbury, Connecticut 06073 (US). ZHANG, Lei; 75 Bourne Street, Auburndale, Massachusetts 02466 (US).
- (74) **Agent:** KLEIMAN, Gabriel L.; Pfizer Inc., 235 East 42nd Street, New York, NY 10017 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Declarations under Rule 4.17:**

- as to the identity of the inventor (Rule 4.17(i))
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

[Continued on next page]

(54) **Title:** HETEROAROMATIC COMPOUNDS AS DOPAMINE D1 LIGANDS

(57) **Abstract:** The present invention provides, in part, compounds of Formula I and pharmaceutically acceptable salts thereof and *N*-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or *N*-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.



---

**Published:**

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))